CClinicalTrials.gg
TerminatedNCT03924622Updated May 16, 2022Results posted

Pressure Injury Prevention in AE and PFC

An interventional study of Mepilex and LiquiCell in Pressure Injury and Military Activity, sponsored by University of Washington. Terminated at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-05-16.

Sponsored by University of Washington · Not applicable, Interventional, and Other

Why this study was terminated
Unable to continue to conduct study procedures due to pandemic
Phase
Not applicable
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study evaluates the effect of a multilayer skin dressing (Mepilex) placed on the sacrum or a fluid filled pad (LiquiCell) on risk factors for pressure injuries under conditions consistent with military long-distance transport or prolonged field care. Participants will be assigned to one of six groups - air transport, air transport on a spinal immobilization surface with or without Mepilex or on a field stretcher with or without LiquiCell.

Read the detailed description

Combat casualties undergoing long distance aeromedical evacuation (AE), particularly casualties who are immobilized because of possible spine injuries, and casualties who required prolonged field care are at increased risk for pressure injuries. The risk factors pressure and shear are potentially modifiable via solutions appropriate for these austere conditions. Two interventions (Mepilex and LiquiCell) will be evaluated under conditions simulating military medical transport on a standard stretcher or with spinal immobilization in a vacuum spine board (VSB) or on a military stretcher used under field conditions. Mepilex is a multi-layer dressing that can be placed on the skin (sacrum/buttocks) and LiquiCell is a pad filled with pockets of fluid that is placed under the back and buttocks. The effect of these interventions compared to not using them will be studied under the three conditions with or without the intervention (Mepilex or LiquiCell) using measures obtained on the lower back/sacrum including skin interface pressure, oxygen, moisture, and temperature and a cytokine indicating possible tissue damage.

02

Conditions studied

  • Pressure Injury
  • Military Activity

Keywords

  • Pressure injury/prevention
  • Military Nursing
  • Risk Reduction
03

In context

Pressure Ulcer

518 studies on the registry are indexed under Pressure Ulcer; 117 are open to participants now.

This study's enrollment of 72 is close to the median of 70 across 395 interventional studies indexed under Pressure Ulcer.

Browse Pressure Ulcer studies →

Lead sponsor

University of Washington is the lead sponsor of 1,397 studies on the registry; 225 are open to participants now.

Of its 154 completed or terminated interventional studies of FDA-regulated products, 132 (86%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Men and women
  • Age 18 to 55
  • Meet the physical standards for military personnel
  • Weigh less than 250 pounds
  • Be able to remain in the study position for the duration of the study.

Exclusion criteria

Exclusion Criteria

  • Previous injuries to sacrum/buttocks with scarring
  • History of pressure injuries
  • Cardiovascular disease
  • Neurological disease that would affect vascular response
  • Diabetes
  • History of malignancy
  • Current skin condition (e.g., eczema or psoriasis)
  • Current neck/back pain or history of chronic neck/back pain
  • Known vertebral/spinal cord disease/injury (scoliosis, kyphosis, or lordosis)
  • Self-reported pregnancy
  • Concern about ability to remain in the vacuum spine board for 120 minutes
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Group 1: Mepilex on Litter + AE Mattress + 30 degree backrest

    Intervention: Mepilex

    Device: Mepilex

  • No intervention
    Group 2: Without Mepilex on Litter + AE mattress + backrest

    Intervention: Control (no Mepilex)

  • Experimental
    Group 3: Mepilex on VSB on AE mattress

    Intervention: Mepilex

    Device: Mepilex

  • No intervention
    Group 4: Without Mepilex on VSB on AE mattress

    Intervention: Control (no Mepilex)

  • Experimental
    Group 5 Prolonged Field Care (PFC) - LiquiCell on Talon litter

    Intervention: LiquiCell mat

    Device: LiquiCell

  • No intervention
    Group 6: PFC Without LiquiCell on Talon Litter

    Intervention: Control (no LiquiCell)

Interventions

  • DeviceMepilex

    Mepilex Border Sacrum dressing is a multi-layered soft silicone dressing that is a recommended strategy to augment standard nursing interventions (i.e., repositioning, offloading) to prevent pressure injuries. The dressing will be placed on the sacrum.

  • DeviceLiquiCell

    LiquiCell is a thin layer of low-viscosity fluid contained in a series of bursa-like pouches. Baffles within each pouch channel the liquid to disperse pressure and the volume of liquid in the pouch is so small that there is no pressure-build up. LiquiCell is available commercially as a 36 X 18-inch mattress overlay (LiquiCell Shear Reducing Mattress Overlay) with a soft pliable top and a non-slip bottom. The overlay is positioned from the shoulders to below the hips to minimize shear.

06

What researchers measure

Primary outcomes

  1. Change in Interleukin-1/Total Protein (Skin)

    Skin cytokine (IL-1) and total protein will be obtained using a small strip of specialized tape placed on the sacrum/buttocks. After 1-minute application the tape is removed and analyzed for quantity of interleukin-1 (indicator of skin irritation)

    Time frame: Baseline through study completion - approximately 120 minutes

  2. Change in Transcutaneous Tissue Oxygen (TcPO2)

    Tissue oxygen is measured continuously on the sacrum using a noninvasive sensor and on the midsternum (midchest) as a control

    Time frame: Measured continuously during the baseline (sidelying), supine (120 minutes) and post-sidelying (15 minutes) periods

  3. Change in Skin Moisture (Epidermal and Subepidermal)

    Two components of skin moisture will be measured on the sacrum using the Delfin MoistureMeter. The epidermal moisture, which reflects perspiration and subepidermal moisture , which reflects water content of the tissues. The values range from 1-80, with higher numbers reflecting increased moisture.

    Time frame: Baseline (before lying down) and after 120 minutes supine

  4. Change in Skin Temperature

    Skin temperature will be measured continuously on the sacrum using a laser doppler probe.

    Time frame: Measured continuously during the baseline (sidelying), supine (120 minutes) and post-sidelying (15 minutes) periods

  5. Change in Skin Interface Pressure

    The pressure between the support surface and the skin will be measured continuously during the supine position using the X Sensor system. This system measures force/unit area (e.g., pressure). The peak and average pressure on the sacrum/buttocks will be measured.

    Time frame: Continuously during the supine phase of the study (120 minutes)

Secondary outcomes

  1. Change in Pressure-Discomfort (Category Partitioning Scale-50)

    This scale asks the participant to describe in verbal terms the pressure intensity or discomfort associated with the stimulus (i.e., sacral/buttocks pressure or discomfort). The participant can then fine tune their assessment using a numeric score. The final score is an analog. The score ranges from 0-52, with higher scores indicating higher pressure or more severe discomfort. The investigator will ask the participant to limit their evaluation to the pressure/discomfort sensed on the sacrum/buttocks, but the investigator will also ask the participants to identify on their body where they are experiencing the most pressure/discomfort.

    Time frame: The score will be obtained at baseline and every 30 minutes in the supine position (total 5 measurements).

07

Results

Posted May 16, 2022

Participant flow

Participant flow — Overall Study
MilestoneGroup 1: Mepilex on Litter + WELP Mattress + 30 Degree BackrestGroup 2: Without Mepilex on Litter + WELP Mattress +30 Degree BackrestGroup 3: Mepilex on VSB on WELP MattressGroup 4: Without Mepilex on VSB on WELP MattressGroup 5 Prolonged Field Care (PFC) - LiquiCell on Talon LitterGroup 6: PFC Without LiquiCell on Talon Litter
Started121212121212
Completed1099899
Not completed233433
Withdrew: Study closed due to pandemic with approval of funding agency/irb233433

Outcome measures

PrimaryChange in Interleukin-1/Total Protein (Skin)

Skin cytokine (IL-1) and total protein will be obtained using a small strip of specialized tape placed on the sacrum/buttocks. After 1-minute application the tape is removed and analyzed for quantity of interleukin-1 (indicator of skin irritation)

Time frame:
Baseline through study completion - approximately 120 minutes
Reported as:
Mean · Ratio
Change in Interleukin-1/Total Protein (Skin)
RatioGroup 1: Mepilex on Litter + WELP Mattress + 30 Degree BackrestGroup 2: Without Mepilex on Litter + WELP Mattress +30 Degree BackrestGroup 3: Mepilex on VSB on WELP MattressGroup 4: Without Mepilex on VSB on WELP MattressGroup 5 Prolonged Field Care (PFC) - LiquiCell on Talon LitterGroup 6: PFC Without LiquiCell on Talon Litter
Change in Interleukin-1/Total Protein (Skin)-1.9 ± 2.7-0.8 ± 2.70.13 ± 2.4-4 ± 2.2-3.5 ± 2.70.14 ± 0.3
PrimaryChange in Transcutaneous Tissue Oxygen (TcPO2)

Tissue oxygen is measured continuously on the sacrum using a noninvasive sensor and on the midsternum (midchest) as a control

Time frame:
Measured continuously during the baseline (sidelying), supine (120 minutes) and post-sidelying (15 minutes) periods
Reported as:
Mean · mm Hg
Change in Transcutaneous Tissue Oxygen (TcPO2)
mm HgGroup 1: Mepilex on Litter + WELP Mattress + 30 Degree BackrestGroup 2: Without Mepilex on Litter + WELP Mattress +30 Degree BackrestGroup 3: Mepilex on VSB on WELP MattressGroup 4: Without Mepilex on VSB on WELP MattressGroup 5 Prolonged Field Care (PFC) - LiquiCell on Talon LitterGroup 6: PFC Without LiquiCell on Talon Litter
Change in Transcutaneous Tissue Oxygen (TcPO2)-15 ± 26-25 ± 25-4 ± 23-6 ± 16-54 ± 24-53 ± 17
PrimaryChange in Skin Moisture (Epidermal and Subepidermal)

Two components of skin moisture will be measured on the sacrum using the Delfin MoistureMeter. The epidermal moisture, which reflects perspiration and subepidermal moisture , which reflects water content of the tissues. The values range from 1-80, with higher numbers reflecting increased moisture.

Time frame:
Baseline (before lying down) and after 120 minutes supine
Reported as:
Mean · Tissue Dielectric Constant (TDC)
Change in Skin Moisture (Epidermal and Subepidermal)
Tissue Dielectric Constant (TDC)Group 1: Mepilex on Litter + WELP Mattress + 30 Degree BackrestGroup 2: Without Mepilex on Litter + WELP Mattress +30 Degree BackrestGroup 3: Mepilex on VSB on WELP MattressGroup 4: Without Mepilex on VSB on WELP MattressGroup 5 Prolonged Field Care (PFC) - LiquiCell on Talon LitterGroup 6: PFC Without LiquiCell on Talon Litter
Change in Skin Moisture (Epidermal and Subepidermal)1.5 ± 22 ± 3.81.1 ± 2.22.1 ± 2.8-0.1 ± 20.1 ± 1.3
PrimaryChange in Skin Temperature

Skin temperature will be measured continuously on the sacrum using a laser doppler probe.

Time frame:
Measured continuously during the baseline (sidelying), supine (120 minutes) and post-sidelying (15 minutes) periods
Reported as:
Mean · Degrees centigrade
Change in Skin Temperature
Degrees centigradeGroup 1: Mepilex on Litter + WELP Mattress + 30 Degree BackrestGroup 2: Without Mepilex on Litter + WELP Mattress +30 Degree BackrestGroup 3: Mepilex on VSB on WELP MattressGroup 4: Without Mepilex on VSB on WELP MattressGroup 5 Prolonged Field Care (PFC) - LiquiCell on Talon LitterGroup 6: PFC Without LiquiCell on Talon Litter
Change in Skin Temperature3.8 ± 1.33.1 ± 13.7 ± 0.83.2 ± 12 ± 21.1 ± 0.9
PrimaryChange in Skin Interface Pressure

The pressure between the support surface and the skin will be measured continuously during the supine position using the X Sensor system. This system measures force/unit area (e.g., pressure). The peak and average pressure on the sacrum/buttocks will be measured.

Time frame:
Continuously during the supine phase of the study (120 minutes)
Reported as:
Mean · mm Hg
Change in Skin Interface Pressure
mm HgGroup 1: Mepilex on Litter + WELP Mattress + 30 Degree BackrestGroup 2: Without Mepilex on Litter + WELP Mattress +30 Degree BackrestGroup 3: Mepilex on VSB on WELP MattressGroup 4: Without Mepilex on VSB on WELP MattressGroup 5 Prolonged Field Care (PFC) - LiquiCell on Talon LitterGroup 6: PFC Without LiquiCell on Talon Litter
Change in Skin Interface Pressure46 ± 852 ± 1052 ± 1066 ± 2266 ± 2778 ± 47
SecondaryChange in Pressure-Discomfort (Category Partitioning Scale-50)

This scale asks the participant to describe in verbal terms the pressure intensity or discomfort associated with the stimulus (i.e., sacral/buttocks pressure or discomfort). The participant can then fine tune their assessment using a numeric score. The final score is an analog. The score ranges from 0-52, with higher scores indicating higher pressure or more severe discomfort. The investigator will ask the participant to limit their evaluation to the pressure/discomfort sensed on the sacrum/buttocks, but the investigator will also ask the participants to identify on their body where they are experiencing the most pressure/discomfort.

Time frame:
The score will be obtained at baseline and every 30 minutes in the supine position (total 5 measurements).
Reported as:
Mean · Scores on a scale
Change in Pressure-Discomfort (Category Partitioning Scale-50)
Scores on a scaleGroup 1: Mepilex on Litter + WELP Mattress + 30 Degree BackrestGroup 2: Without Mepilex on Litter + WELP Mattress +30 Degree BackrestGroup 3: Mepilex on VSB on WELP MattressGroup 4: Without Mepilex on VSB on WELP MattressGroup 5 Prolonged Field Care (PFC) - LiquiCell on Talon LitterGroup 6: PFC Without LiquiCell on Talon Litter
Change in Pressure-Discomfort (Category Partitioning Scale-50)7.7 ± 8.18 ± 10.49.1 ± 7.35.4 ± 4.28.7 ± 13.412.3 ± 11.1

Adverse events

Collected over 120 minutes. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1: Mepilex on Litter + WELP Mattress + 30 Degree Backrest0/10 (0%)0/10 (0%)0/10 (0%)
Group 2: Without Mepilex on Litter + WELP Mattress +30 Degree Backrest0/9 (0%)0/9 (0%)0/9 (0%)
Group 3: Mepilex on VSB on WELP Mattress0/9 (0%)0/9 (0%)0/9 (0%)
Group 4: Without Mepilex on VSB on WELP Mattress0/8 (0%)0/8 (0%)0/8 (0%)
Group 5 Prolonged Field Care (PFC) - LiquiCell on Talon Litter0/9 (0%)0/9 (0%)0/9 (0%)
Group 6: PFC Without LiquiCell on Talon Litter0/9 (0%)0/9 (0%)0/9 (0%)

Baseline characteristics

All individuals with baseline data

Age, Continuous
Age, Continuous(years)Group 1: Mepilex on Litter + WELP Mattress + 30 Degree BackrestGroup 2: Without Mepilex on Litter + WELP Mattress +30 Degree BackrestGroup 3: Mepilex on VSB on WELP MattressGroup 4: Without Mepilex on VSB on WELP MattressGroup 5 Prolonged Field Care (PFC) - LiquiCell on Talon LitterGroup 6: PFC Without LiquiCell on Talon LitterTotal
Mean29.0 ± 10.626.7 ± 7.325.3 ± 12.324.8 ± 5.923.9 ± 8.825 ± 829 ± 12
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: Mepilex on Litter + WELP Mattress + 30 Degree BackrestGroup 2: Without Mepilex on Litter + WELP Mattress +30 Degree BackrestGroup 3: Mepilex on VSB on WELP MattressGroup 4: Without Mepilex on VSB on WELP MattressGroup 5 Prolonged Field Care (PFC) - LiquiCell on Talon LitterGroup 6: PFC Without LiquiCell on Talon LitterTotal
Female86666840
Male23323114
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group 1: Mepilex on Litter + WELP Mattress + 30 Degree BackrestGroup 2: Without Mepilex on Litter + WELP Mattress +30 Degree BackrestGroup 3: Mepilex on VSB on WELP MattressGroup 4: Without Mepilex on VSB on WELP MattressGroup 5 Prolonged Field Care (PFC) - LiquiCell on Talon LitterGroup 6: PFC Without LiquiCell on Talon LitterTotal
Hispanic or Latino0100001
Not Hispanic or Latino108989953
Unknown or Not Reported0000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group 1: Mepilex on Litter + WELP Mattress + 30 Degree BackrestGroup 2: Without Mepilex on Litter + WELP Mattress +30 Degree BackrestGroup 3: Mepilex on VSB on WELP MattressGroup 4: Without Mepilex on VSB on WELP MattressGroup 5 Prolonged Field Care (PFC) - LiquiCell on Talon LitterGroup 6: PFC Without LiquiCell on Talon LitterTotal
American Indian or Alaska Native0000000
Asian35554426
Native Hawaiian or Other Pacific Islander0000000
Black or African American1000001
White63325524
More than one race0001001
Unknown or Not Reported0110002
Body Fat Percent
Body Fat Percent(Percent body fat)Group 1: Mepilex on Litter + WELP Mattress + 30 Degree BackrestGroup 2: Without Mepilex on Litter + WELP Mattress +30 Degree BackrestGroup 3: Mepilex on VSB on WELP MattressGroup 4: Without Mepilex on VSB on WELP MattressGroup 5 Prolonged Field Care (PFC) - LiquiCell on Talon LitterGroup 6: PFC Without LiquiCell on Talon LitterTotal
Mean29 ± 10.626.7 ± 7.325.3 ± 12.324.8 ± 5.923.9 ± 8.825.0 ± 8.025.8 ± 8.9
08

Study locations

1 site
  • University of Washington School of Nursing
    Seattle, Washington 98195, United States
09

References and documents

Publications

  • Bridges E, Whitney JD, Burr R, Tolentino E. Reducing the Risk for Pressure Injury During Combat Evacuation. Crit Care Nurse. 2018 Apr;38(2):38-45. doi: 10.4037/ccn2018223. PubMed 29606674 ↗

Study documents

  • Study protocol · Jan 4, 2019
  • Statistical analysis plan · Jan 4, 2019

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03924622
Lead sponsor
University of Washington
Responsible party
Elizabeth Bridges (Professor, School of Nursing: Dept: Biobehavioral Nursing and Health Informatics, University of Washington) — Principal investigator
First posted
Apr 23, 2019
Start date
Jul 20, 2019
Primary completion
Sep 23, 2020
Completion
Sep 23, 2020
Results posted
May 16, 2022
Last update
May 16, 2022

Study contacts

Elizabeth Bridges, PhD, RN
principal investigator · University of Washington

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion